Contact tracing for COVID-19 is the process of identifying, assessing, and managing people who have been exposed to someone who has been infected with the SARS-CoV-2 virus, while quarantine is the separation of contacts from other people after exposure to a probable or confirmed case of SARS-CoV-2 i...nfection. In the context of growing global population immunity from COVID-19 vaccination and past SARS-CoV-2 infection, WHO recommends that identification, contact, quarantine and follow-up should be prioritized for individuals at high risk who have been in contact with a confirmed or probable case of SARS-CoV-2 infection, rather than targeting all contacts. This updated guidance also introduces shorter recommended quarantine periods, including the ability to further shorten quarantine through the use of testing. National and local health authorities should use risk-based approaches to contact tracing and quarantine that include reviewing and adjusting to their local circumstances and disease epidemiology, population immunity, their health system’s capacities, and risk tolerance.
more
access free courses in more than 60 languages
This report - the largest of its kind to date - draws on the experiences of over 8,500 women and 300 health professionals across eight countries. It exposes the aggressive marketing practices used by the formula milk industry, and highlights impacts... on families’ decisions about how to feed their babies and young children.
more
Weekly Epidemiological Record No 9, 2022, 97, 61–80
This position paper supersedes the 2016 publication, “Malaria vaccine: WHO position paper-2016.”1 It includes the updated WHO recommendations on the wider use of the RTS,S/AS01 vaccine for the reduction of malaria morbidity and mortality in ...children living in areas of moderate to high malaria transmission. It also incorporates findings from the evaluation of the WHO-coordinated Malaria Vaccine Implementation Programme (MVIP), recommended by SAGE and MPAG in 2015, and from additional studies since 2015.
This paper does not include findings on vaccine efficacy in infants first vaccinated at 6–12 weeks of age. Because of the lower vaccine efficacy observed in this age category, WHO did not recommend pilot implementation or RTS,S/AS01 vaccine introduction for these young infants. Recommendations2 on the use of RTS,S/AS01 vaccine were discussed by SAGE and MPAG during a joint session in October 2021; evidence presented at the meeting can be accessed at https://terrance.who.int/mediacentre/data/ sage/SAGE_eYB_Oct2021.pdf
more
dades infecciosas. Los antimicrobianos eficaces son imprescindibles para las medidas preventivas y curativas, para proteger a los pacientes frente a enfermedades potencialmente mortales y para garantizar que se puedan llevar a cabo procedimientos complejos, como la cirugía y la quimioterapia, con e...scasos riesgos. Sin embargo, el mal uso y el abuso sistemático de estos fármacos en la medicina y la producción de alimentos han puesto en riesgo a todas las naciones. Hay pocos productos de recambio en fase de investigación y desarrollo. Sin medidas armonizadas e inmediatas a escala mundial avanzamos hacia una era posantibiótica en la que infecciones comunes podrían volver a ser mortales.
more
En 2015, el 26% de los decesos de 5,9 millones de niños que murieron antes de cumplir los cinco años podría haberse prevenido
abordando los riesgos medioambientales; una impactante oportunidad perdida. El período prenatal y de la primera infancia
representa un escenario de particular vulnerabi...lidad, donde los peligros medioambientales pueden conducir al parto prematuro y otras complicaciones, y aumentar el riesgo de desarrollar una enfermedad de por vida, como enfermedades respiratorias, enfermedades cardiovasculares y cáncer. De este modo, el medio ambiente representa un factor importante en la salud infantil, así como una gran oportunidad de implementar mejoras, con efectos observados en cada región del mundo
more
La finalidad de estas orientaciones es aumentar la capacidad de los establecimientos de salud para proteger y mejorar la salud de las comunidades destinatarias ante un clima inestable y cambiante;
y habilitarlos para que sean ambientalmente sostenibles, optimizando el uso de los recursos y reducien...do al mínimo el vertido de desechos en el medio ambiente. Los establecimientos de salud resilientes al clima y ambientalmente sostenibles favorecen una atención de alta calidad
así como la accesibilidad de los servicios, y al ayudar a reducir los costos también garantizan una mejor asequibilidad. Por consiguiente, son un componente importante de la cobertura sanitaria universal (CSU).
El presente documento tiene por objeto:
Orientar a los profesionales que trabajan en el ámbito de la atención de salud a fin de que comprendan los riesgos sanitarios adicionales que entraña el cambio climático y se preparen eficazmente para afrontarlos.
Fortalecer la capacidad para llevar a cabo una vigilancia eficaz de las enfermedades relacionadas con el clima; y vigilar, prever y gestionar los riesgos para la salud asociados al cambio climático y adaptarse a ellos.
Guiar al personal de los establecimientos de salud para que trabaje con los sectores determinantes de la salud (en particular los de agua y saneamiento, energía, transporte, alimentación, planificación urbana y medio ambiente) a fin de que se prepare para afrontar los riesgos sanitarios adicionales que entraña el cambio climático mediante un enfoque de resiliencia, y promueva prácticas ambientalmente sostenibles en la prestación de los servicios.
Proporcionar al personal de los centros salud instrumentos que le ayuden a evaluar la resiliencia de los establecimientos ante las amenazas del cambio climático y su sostenibilidad ambiental a partir del uso adecuado de los recursos (en particular el agua y la energía y las adquisiciones sostenibles) y el vertido de desechos peligrosos (biológicos, químicos y radiológicos) en el medio circundante.
Promover medidas encaminadas al fortalecimiento constante y creciente de los establecimientos de salud y a garantizar que sigan siendo eficientes y responsivos para mejorar la salud y
contribuyan a reducir las inequidades y la vulnerabilidad en los entornos en que están implantados.
more
Any individual that meets the suspected case definition of monkeypox should be offered testing in appropriately equipped laboratories by staff trained in the relevant technical and safety procedures. Confirmation of monkeypox virus infection is based on nucleic acid amplification testing (NAAT), usi...ng real-time or conventional polymerase chain reaction (PCR), for detection of unique sequences of viral DNA. PCR can be used alone, or in combination with sequencing. The recommended specimen type for laboratory confirmation of monkeypox is skin lesion material, including swabs of lesion surface and/or exudate, roofs from more than one lesion, or lesion crusts.
more
The goal of the global outbreak response for monkeypox is to stop human-to-human transmission of monkeypox, with a priority focus on communities at high risk of exposure which may differ according to context, and to effectively use strong public health...an> measures to prevent onward spread of the disease. Judicious use of vaccines can support this response. This interim guidance, developed with the advice and support of the Strategic Advisory Group of Experts (SAGE) Working Group on smallpox and monkeypox vaccines, provides the first WHO recommendations on vaccines and immunization for monkeypox. Key points follow.
more
Severe bacterial infections are a leading cause of morbidity and mortality among people with advanced HIV disease, after tuberculosis and cryptococcal disease. For countries to reach the end-AIDS targets for 2030, there is a need to establish a roadmap for managing severe bacterial infections and re...duce mortality. The purpose of the meeting was to
Review the current research and implementation data on the use of prophylactic antibiotics (specifically azithromycin/macrolides) as part of the AHD package of care; To review options for preventing SBIs that are in line with goals of reducing AMR; Present the current evidence on diagnostics for SBI; Discuss research gaps and implementation challenges.
more
This report presents an analysis of antibacterial agents in preclinical (third annual review) and clinical (fifth annual review) development. The analysis covers traditional (direct-acting small molecules) and non-traditional antibacterial agents in development worldwide. It evaluates to what extent... the present pipeline addresses infections caused by WHO Priority Pathogens, Mycobacterium tuberculosis and Clostridioides difficile. The report also provides an assessment of the traditional agents with respect to whether they meet a set of predefined criteria for innovation, namely absence of known cross-resistance, new target, mode of action and/or class. It also includes an overview of the agents that obtained authorization since 1 July 2017.
more
This annual report highlights the work of the WHO from January to June 2021 ( December 2021). The activities featured herein are by no means exhausted but implemented with technical and financial support through WHO in Nigeria; facilitated by its presence at all levels of governance (national, state..., local government, and wards).
more
Antimicrobial resistance (AMR) is described as a situation when bacteria, viruses, fungi and parasites
change over time and no longer respond to medicines, making infections harder or impossible to treat,
and increasing the risk of disease spread, severe illness and death.1 AMR in recent years has... become
a global priority in public health due to its widespread consequences and increasing occurrence from
time to time. AMR has a formidable impact where the existing antibiotics and other antimicrobial
medicines become ineffective, and infections become increasingly difficult or impossible to treat.
more
first issued 18 August 2022
Fact Sheet Global Atlas of medical devices
manual de referencia rápida de anomalías congénitas e infecciones seleccionadas
31 Oct 2022 his plan outlines how the ACT-Accelerator will support countries as the world transitions to long-term COVID-19 control.
Recognizing the evolving nature of the COVID-19 virus and pandemic, the plan outlines changes to ACT-A’s... set-up and ways of working, to ensure countries continue to have access to COVID-19 tools in the longer term, while maintaining the coalition’s readiness to help address future disease surges.
Developed through a consultative process with ACT-A agencies, donors, industry partners, civil society organizations (CSOs) and Facilitation Council members, the plan summarizes priority areas of focus for the partnership’s pillars, coordination mechanisms and other core functions, and highlights the work to be maintained, transitioned, sunset, or kept on standby.
more